SNDX - התחייבויות לטווח ארוך של החברה Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is developing a precision oncology system, integrating unique therapeutics into standard treatment protocols. The company's environmental policy is limited to the regulated disposal of hazardous waste. The company's revenue is driven by the launch of revumenib for the treatment of leukemia, and the 0.62 indicator confirms the current trend. The company's price chart on the GURU.Markets platform clearly demonstrates the asset's market value.

For Syndax Pharmaceuticals (SNDX), which invests in the development of anti-tumor drugs and adheres to environmental waste disposal regulations, long-term liabilities reflect the scale of external financing for R&D cycles. This indicator aggregates all loans with a maturity of more than one year, allowing for an assessment of financial stability and the risk of interest overpayments, as clearly demonstrated by the company's long-term debt history.